Enteropeptidase inhibition improves obesity by modulating gut microbiota composition and enterobacterial metabolites in diet-induced obese mice

• Published in: Pharmacological research 2021-01, Vol.163, p.105337-105337, Article 105337
• Main Authors: Sugama, Jun, Moritoh, Yusuke, Yashiro, Hiroaki, Tsuchimori, Kazue, Watanabe, Masanori
• Format: Article
• Language: English
• Subjects: Akkermansia; Akkermansia - genetics; Animals; Anti-Obesity Agents - pharmacology; Anti-Obesity Agents - therapeutic use; Bile Acids and Salts - metabolism; Diet, High-Fat; Diet, Western; Enterobacteriaceae - metabolism; Enteropeptidase; Enteropeptidase - antagonists & inhibitors; Fatty Acids, Volatile - metabolism; Feces - chemistry; Gastrointestinal Microbiome - drug effects; Gut microbiota; Immunoglobulin A - metabolism; Male; Mice; Mice, Inbred C57BL; Obesity; Obesity - drug therapy; Obesity - microbiology; RNA, Ribosomal, 16S - genetics; Short-chain fatty acid
• ISSN: 1043-6618; 1096-1186
• DOI: 10.1016/j.phrs.2020.105337

[Display omitted] •The inhibition of duodenal enteropeptidase lowers body weight in mice.•Gut microbiota is involved in body weight reduction via enteropeptidase inhibition.•Enteropeptidase inhibition increases the abundance of Akkermansia muciniphila.•Fecal SCFAs, bile acids, and IgA are increased by enteropeptidase inhibition. Enteropeptidase is a transmembrane serine protease localized in the lumen of the duodenum that acts as a key enzyme for protein digestion. SCO-792 is an orally available enteropeptidase inhibitor that has been reported to have therapeutic effects on obesity and diabetes in mice. However, the mechanism underlying the therapeutic effect of SCO-792 has not yet been fully elucidated. In this study, we evaluated the role of gut microbiota on SCO-792-induced body weight (BW) reduction in high-fat diet-induced obese (DIO) mice. Chronic administration of SCO-792 substantially decreased BW and food intake in DIO mice. While the pair-fed study uncovered food intake-independent mechanisms of BW reduction by SCO-792. Interestingly, antibiotics-induced microbiota elimination in the gut canceled SCO-792-induced BW reduction by nearly half without affecting the anorectic effect, indicating the involvement of gut microbiota in the anti-obesity mechanism that is independent of food intake reduction. Microbiome analysis revealed that SCO-792 altered the gut microbiota composition in DIO mice. Notably, it was found that the abundance of Firmicutes decreased while that of Verrucomicrobia increased at the phylum level. Increased abundance of Akkermansia muciniphila, a bacterium known to be useful for host metabolism, was observed in SCO-792-treated mice. Fecal metabolome analysis revealed increased amino acid levels, indicating gut enteropeptidase inhibition. In addition, SCO-792 was found to increase the level of short-chain fatty acids, including propionate, and bile acids in the feces, which all help maintain gut health and improve metabolism. Furthermore, it was found that SCO-792 induced the elevation of colonic immunoglobulin A (IgA) concentration, which may maintain the microbiota condition, in DIO mice. In conclusion, this study demonstrates the contribution of microbiota to SCO-792-induced BW reduction. Enteropeptidase-mediated regulation of microbiota, enterobacterial metabolites, and IgA in the gut may coordinately drive the therapeutic effects of SCO-792 in obesity.